Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Catalent Inc
(NY:
CTLT
)
60.29
+0.20 (+0.33%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Catalent Inc
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
5 Stocks To Watch For August 30, 2021
August 30, 2021
Some of the stocks that may grab investor focus today are: Wall Street expects Zoom Video Communications Inc (NASDAQ: ZM) to report quarterly earnings at $1.16 per share on...
Via
Benzinga
Earnings Scheduled For August 30, 2021
August 30, 2021
Companies Reporting Before The Bell Catalent Inc (NYSE: CTLT) is expected to report quarterly earnings at $1.03 per share on revenue of $1.14 billion. Cloudera, Inc. (NYSE: CLDR...
Via
Benzinga
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
August 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Catalent's Debt Overview
August 25, 2021
Shares of Catalent (NYSE:CTLT) rose by 23.76% in the past three months. Before having a look at the importance of debt, let us look at how much debt Catalent has. Catalent...
Via
Benzinga
Catalent: Q3 Earnings Insights
May 04, 2021
Shares of Catalent (NYSE:CTLT) decreased 0.1% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 64.00% over the past...
Via
Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
May 01, 2021
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
August 26, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
COVID-19
A Look Into Catalent's Price Over Earnings
August 25, 2021
In the current market session, Catalent Inc. (NYSE:CTLT) is trading at $126.21, after a 0.1% drop. However, over the past month, the stock went up by 8.33%, and in...
Via
Benzinga
EMA Approves Additional Sites To Boost Output Capacity For mRNA-Based COVID-19 Vaccines
August 25, 2021
European Medical Agency (EMA) has approved additional manufacturing sites for mRNA-based coronavirus vaccines developed by Pfizer Inc (NYSE: PFE) - ...
Via
Benzinga
Exposures
COVID-19
Unusual Options Activity Insight: Catalent
August 16, 2021
On Monday, shares of Catalent (NYSE:CTLT) saw unusual options activity. After the option alert, the stock price moved up to $121.14. Sentiment: BEARISH Option Type: TRADE Trade...
Via
Benzinga
Catalent, Inc. Announces Fourth Quarter Fiscal Year 2021 Earnings Conference Webcast
August 06, 2021
From
Catalent, Inc.
Via
Business Wire
Catalent Achieves 97% Renewable Electricity Sourcing and Commits to Science-Based Target Initiative to Reduce Carbon Footprint
August 03, 2021
From
Catalent, Inc.
Via
Business Wire
2 Stocks Insiders Are Buying
July 29, 2021
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go...
Via
Benzinga
Catalent Plans $100M Expansion Of Biologics Capabilities At Italian Vaccine Plant
July 21, 2021
Catalent Inc (NYSE: CTLT) will begin the first phase of a planned $100 million expansion at its facility in Anagni, Italy, to add biologics drug substance manufacturing...
Via
Benzinga
Moderna's COVID-19 Vaccine Produced Neutralizing Titers Against All Variants Tested
June 29, 2021
Moderna Inc (NASDAQ: MRNA) has announced new results from in vitro neutralization studies of sera from individuals vaccinated with its COVID-19 vaccine. The COVID-...
Via
Benzinga
Exposures
COVID-19
5 Top ETFs With Exposure To Biogen
June 07, 2021
For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that...
Via
Benzinga
Exposures
Product Safety
Catalent, Inc. to Present at the Biopharma CEO Investor Forum
June 04, 2021
From
Catalent, Inc.
Via
Business Wire
AstraZeneca Seeks Switching COVID-19 Vaccine Production to Catalent Plant: NYT
June 03, 2021
AstraZeneca Plc (NASDAQ: AZN) is in talks with the U.S. government to shift production of its COVID-19 vaccine from a troubled Emergent BioSolutions Inc’s (...
Via
Benzinga
Exposures
COVID-19
Catalent, Inc. to Present at the Jefferies Healthcare Conference and the William Blair Growth Stock Conference
May 28, 2021
From
Catalent, Inc.
Via
Business Wire
Catalent, Inc. to Present at the UBS Global Healthcare Virtual Conference
May 21, 2021
From
Catalent, Inc.
Via
Business Wire
Catalent Publishes Second Annual Corporate Responsibility Report Highlighting Achievements in an Extraordinary Year for the Pharmaceutical Industry
May 13, 2021
From
Catalent, Inc.
Via
Business Wire
Catalent Announces Chief Financial Officer Succession
May 11, 2021
From
Catalent, Inc.
Via
Business Wire
FDA Outlines Plan For Restarting Facility Inspections Halted Due To Pandemic
May 10, 2021
The FDA has published a roadmap for working through the backlog of facility inspections built up during the pandemic when it postponed all routine inspections in March...
Via
Benzinga
Exposures
Product Safety
Catalent, Inc. to Present at the BofA Securities 2021 Health Care Conference
May 07, 2021
From
Catalent, Inc.
Via
Business Wire
Catalent Buys Promethera's Cell Therapy Subsidiary To Scale-Up Plasmid DNA Efforts
May 06, 2021
Catalent Inc (NYSE: CTLT) has been expanding rapidly in next-gen cell therapies, and now it has added another facility in Belgium as part of its plan to...
Via
Benzinga
Catalent Inc (CTLT) Q3 2021 Earnings Call Transcript
May 04, 2021
CTLT earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Catalent, Inc. Reports Third Quarter Fiscal 2021 Results
May 04, 2021
From
Catalent, Inc.
Via
Business Wire
Moderna Tries To Boost COVID-19 Vaccine Supply Chain To Produce 3B Doses Annually
April 29, 2021
Moderna Inc (NASDAQ: MRNA) plans to produce up to 3 billion doses in 2022, doubling capacity at contract sites in Switzerland and Spain run by Lonza Group...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
May 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Moderna Stock Near Breakout As Company Boosts Its Covid Vaccines Outlook
April 29, 2021
Moderna boosted its forecast for Covid vaccine doses in 2021 and 2022, in a move early Thursday that could send Moderna stock into a breakout.
Via
Investor's Business Daily
Exposures
COVID-19
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.